4 Things to Know About Intellectual Property and COVID-19 Vaccines; U.S. Chamber of Commerce, December 9, 2021

U.S. Chamber of Commerce; 4 Things to Know About Intellectual Property and COVID-19 Vaccines

Intellectual property enabled the discovery of lifesaving COVID-19 vaccines. Here’s why calls to waive IP rights would undermine medical innovation and our ability to respond to the next pandemic.

"Key takeaways

• Some governments, including the United States, are considering a proposal to waive intellectual property laws for COVID-19 vaccines.
• But waiving intellectual property laws could jeopardize medical innovation, including the development of new or adapted vaccines to combat COVID-19 variants like Omicron.
• Waiving intellectual property rights for COVID vaccines could have ripple effects on innovators and investments across industries."

Louisiana considers radical step to counter high drug prices: Federal intervention; Washington Post, July 3, 2017

Carolyn Y. Johnson, Washington Post; Louisiana considers radical step to counter high drug prices: Federal intervention

"Gilead, a company that has projected between $7.5 billion and $9 billion in sales for 2017 for its hepatitis C drugs, says federal intervention would threaten future progress.

In a statement, the company said the proposal “puts in jeopardy further medical innovation by undermining the patent system and de-incentivizing research and development.” Gilead said that the state’s predictions of the budget impact are unrealistic, based on the idea that the entire infected population could be screened, treated and connected to treatment in a year. Gilead offers states that do not restrict access to treatments deep discounts — less than $30,000 for a 12-week treatment...

Gee said that she is not wedded to one approach and that she simply thinks the equity and access problems that are an outgrowth of high drug prices need to be tackled. After receiving the expert panel’s recommendation, Gee put out the proposal for public comment and received 102, a majority of which were in favor of taking some action. She expects to make a decision soon about a strategy to try to eliminate hepatitis C in Louisiana."

Patent rights key to ensuring access to medication; Trib Live, 10/24/16

Robert A. Freeman, Trib Live; Patent rights key to ensuring access to medication:

" A United Nations panel recently released disastrous policy recommendations designed to increase access to medicines in developing countries. The panel ignored obvious solutions.

Secretary General Ban Ki-Moon originally tasked the UN High-Level Panel on Access to Medicines with remedying the “policy incoherence” between intellectual property rights and drug access. The panel predictably — and wrongly — viewed IP protections as a barrier to access rather than a bridge to medical innovation.

Undermining IP rights will not help patients in developing countries access medicines.

A 2016 Foreign Affairs study sought to determine whether strong patent protections increase the prices of drugs to developing countries. It found that patents were not key drivers of higher expenditures."